Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1149 details
Primary information
ID1653
ThPP IDTh1149
Therapeutic Peptide/Protein NameRagweed Pollen Extract
SequenceN.A. view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightN.A.
Chemical FormulaN.A.
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
Indication/DiseaseInvestigated for use/treatment in allergic reaction.
PharmacodynamicsPrecise mechanism of allergen immunotherapy is not known
Mechanism of ActionRagweed pollen extract is the oral immunotherapy delivered via microencapsulated beads put into a capsule, which enables the antigen to be delivered more efficiently to the Peyer's patches in the jejunum and duodenum, where the antigen can be presented and processed and not destroyed by stomach acid.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameRagwitek
CompanyMerck Sharp & Dohme
Brand DiscriptionRagwitek tablets contain pollen allergen extract from Short Ragweed (Ambrosia artemisiifolia). It is a sublingual orally disintegrating tablet that dissolves rapidly. It is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract.
Prescribed forRagwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or withoutconjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceTablets
Route of AdministrationOral route
Recommended DosageOne ragwitek tablet daily.
ContraindicationRagwitek is contraindicated in patients with severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction after taking any sublingual allergen immunotherapy, history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product.
Side EffectsThroat irritation, oralpruritus, ear pruritus, oral paraesthesia, mouth edema, and tongue pruritus.
Useful Linkhttp://www.rxlist.com/ragwitek-drug/indications-dosage.htm
PubMed ID12811019, 8760779
3-D StructureN.A.